

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 715 856 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

12.06.1996 Bulletin 1996/24

(51) Int. Cl.⁶: **A61K 47/08**, A61K 47/14,
A61K 47/44

(21) Application number: **95916014.4**

(86) International application number:
PCT/JP95/00773

(22) Date of filing: **19.04.1995**

(87) International publication number:
WO 95/30440 (16.11.1995 Gazette 1995/49)

(84) Designated Contracting States:

**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **06.05.1994 JP 94243/94**

12.12.1994 JP 307521/94

(72) Inventors:

- **KAMISHITA, Takuzo**
Takatsuki-shi, Osaka 569 (JP)
- **MIYAZAKI, Takashi**
Nakaniikawa-gun, Toyama 930-03 (JP)

(71) Applicant: **TOKO YAKUHI KOGYO KABUSHIKI
KAISHA**

Osaka-shi, Osaka 530 (JP)

(74) Representative: **Kraus, Walter, Dr. et al**
Patentanwälte Kraus, Weisert & Partner
Thomas-Wimmer-Ring 15
D-80539 München (DE)

(54) KERATIN-STORABLE ANTIFUNGAL COMPOSITION FOR EXTERNAL USE

(57) A keratin-storable antifungal composition for external use, which contains an antifungal with a high keratin affinity as the active ingredient and also contains at least one liquid oily substance selected from among methyl salicylate, glycol salicylate, crotamiton, mentha oil and methol, and wherein the antifungal has an enhanced capability of penetrating into kerating and is improved in the restorability therein.

EP 0 715 856 A1

DescriptionTechnical Field

5 The present invention relates to an antifungal composition for external use containing as an active ingredient an antifungal agent having a high affinity for keratin. More particularly, the present invention relates to an antifungal composition for external use being retentive in the stratum corneum, which contains one or more oily liquid substances selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol, in order to enhance the penetration into the stratum corneum of the active antifungal agent having a high affinity for keratin, by which said antifungal agent is more retentive in the stratum corneum.

Background Art

15 In superficial mycosis, fungi invade mainly into the epidermal stratum corneum, and grow therein. Thus, in order to exhibit excellent pharmacological activities in the treatment of superficial mycosis, antifungal agents should stay in a high concentration in the infected epidermal stratum corneum for a prolonged time, in addition to their potent antifungal activity.

20 Recently, in order to achieve the above purpose, there have been developed and practically been used antifungal agents having a high affinity for keratin, which exhibit clinical effects thereof in the treatment of superficial mycosis only by a single application per day. However, in order to obtain a sufficient affinity for the epidermal stratum corneum, antifungal agents should be formulated so that they can penetrate into the epidermal stratum corneum. However, these antifungal agents having a high affinity for keratin are quite hardly-soluble, and it is difficult to increase their solubility when incorporated in the base. As a result, the penetration into the epidermal stratum corneum of these agents is not sufficient so as to form an antifungal composition for external use which is retentive in the stratum corneum with utilizing a high affinity for keratin of the active antifungal agent per se at the maximum.

Disclosure of Invention

30 The present inventors have intensively studied in order to improve the penetration into the stratum corneum of antifungal agents having a high affinity for keratin and the retentivity thereof, and have found that when formulating a composition for external use by incorporating one or more oily liquid substances selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol, the active antifungal agents having a high affinity for keratin show an improved penetration into the stratum corneum as well as an improved retentivity in the stratum corneum, and finally have accomplished the present invention.

35 More particularly, it has been found that in the preparation of compositions for external use containing as an active ingredient an antifungal agent having a high affinity for keratin, by incorporating with methyl salicylate, glycol salicylate, crotamiton, peppermint oil or menthol, which can dissolve said antifungal agents well and shows a good penetration into the stratum corneum, the penetration into the epidermal stratum corneum of said antifungal agents is enhanced, and further said antifungal agents are more tightly bound to the components of the epidermal stratum corneum, and fixed thereon.

40 In the composition for external use of the present invention, one or more oily liquid substances selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol can be incorporated thereto by adding and mixing them simultaneously when an antifungal agent having a high affinity for keratin is mixed into a conventional base for external use, but preferably, an antifungal agent having a high affinity for keratin is previously dissolved by using various solvents during which the above mentioned oily liquid substances such as methyl salicylate, etc. are added thereto in an amount sufficient for completely dissolving said antifungal agent, and then the resulting solution is incorporated into a conventional base for external use by a conventional method, and the mixture is mixed and formulated by a conventional method. Alternatively, when an antifungal agent can be completely dissolved in the above mentioned oily liquid substance such as methyl salicylate, etc., said antifungal agent is dissolved in these oily liquid substances without using any other solvent, and then the resulting solution is incorporated into a conventional base for external use. Besides, the above oily liquid substances such as methyl salicylate, etc. used in the present invention are expected to show supplemental pharmacological activities as an external agent by themselves and can enhance the activity of the active antifungal agent more. The menthol may be *l*-menthol, *d*-menthol and *dl*-menthol.

55 The antifungal agent having a high affinity for keratin used in the present invention includes, for example, benzylamine antifungal agents (e.g. butenafine hydrochloride, etc.), imidazole antifungal agents (e.g. bifonazole, neticonazole hydrochloride, ketoconazole, lanoconazole, etc.), allylamine antifungal agents (e.g. terbinafine hydrochloride, etc.), morpholine antifungal agents (e.g. amorolfine hydrochloride, etc.), thiocarbamic acid antifungal agents (e.g. liranafate, etc.), and the like, which is contained in an amount of 0.5 to 3.0 % by weight, preferably in an amount of 1.0 to 2.0 % by weight, based on the whole weight of the composition.

The oily liquid substance used in the present antifungal composition for external use being retentive in the stratum corneum, which is selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol, is used in an amount sufficient for completely dissolving an antifungal agent having a high affinity for keratin during the procedure of previously dissolving said antifungal agent by using various solvents, or in an amount sufficient for completely dissolving said antifungal agent in the case of using no solvent, and it is usually used in an amount of 1.0 to 10 % by weight based on the whole weight of the composition. Moreover, when it is necessary to use a large amount of an oily liquid substance in order to dissolve an antifungal agent having a high affinity for keratin, or when an antifungal agent cannot completely be dissolved in one oily liquid substance, two or more liquid oily substances may be used.

The antifungal composition for external use being retentive in the stratum corneum of the present invention is formulated in any conventional pharmaceutical preparation for epidermic application, i.e. ointment, cream, gel, gel cream, lotion, solution, etc. These preparations may be prepared by a conventional method by using an active antifungal agent having a high affinity for keratin, said oily liquid substances and various conventional bases for external preparations, but preferably, as mentioned above, an antifungal agent is previously dissolved by using one or more oily liquid substances such as methyl salicylate, etc., or by using said oily liquid substances together with other solvents such as a lower alcohol (e.g. ethanol, etc.), a polyvalent alcohol (e.g. 1,3-butylene glycol, polyethylene glycol 400, etc.), an oily liquid substance (e.g. isopropyl myristate, diisopropyl adipate, octyldodecanol, etc.), a surfactant (e.g. laurmacrogol, polyoxyl 40 stearate, etc.), and the like, and the resulting solution is incorporated into a conventional base for external preparations, and mixed and formulated by a conventional method.

For example, in the preparation of an ointment, vaseline, waxes, paraffins, vegetable oils, plastibase, polyethylene glycol, etc. are used as an external base.

In the preparation of a cream preparation, fats and oils, waxes, higher fatty acids, higher alcohols, fatty acid esters, purified water, polyvalent alcohols, emulsifying agents etc. are used.

In the preparation of a gel preparation, there are used gel bases comprising a carboxyvinyl polymer, a water-soluble basic compound (e.g. alkali metal hydroxides, alkanolamines, etc.), hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, purified water, lower alcohols, polyvalent alcohols, polyethylene glycol, and the like.

In the preparation of a gel cream preparation, an emulsifying agent (preferably nonionic surfactants), an oily liquid substance (e.g. liquid paraffin, isopropyl myristate, 2-octyldodecanol, etc.), and the like are used in addition to the above gel bases.

In the preparation of lotion and solution preparations, lower alcohols (e.g. ethanol, isopropanol, etc.) and polyvalent alcohols (e.g. glycerin, propylene glycol, 1,3-butylene glycol, etc.), and purified water are used.

In any of the above preparations, any other conventional additives to be usually incorporated into the epidermic preparations, such as antioxidants, preservatives, humectants, chelating agents, and the like, may also be incorporated. Those preparations may be prepared under the conventional conditions for the conventional epidermic preparations.

Best Mode for Carrying Out the Invention

The composition of the present invention is illustrated in more detail by the following Examples.

Example 1 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	1.0
Glycol salicylate	3.0
Cetostearyl alcohol	5.0
White vaseline	91.0
Totally	100.0 g

EP 0 715 856 A1

Cetostearyl alcohol and white vaseline are dissolved by warming on a water bath, and thereto is added a solution of bifonazole in glycol salicylate which is prepared by warming at about 70 to 80°C, and the mixture is well stirred, and thereafter, cooled and kneaded until it becomes semisolid to give an ointment.

Example 2 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Ketoconazole	0.5
Crotamiton	5.0
Glycol salicylate	3.0
Plastibase	91.5
Totally	100.0 g

To plastibase is added a solution of ketoconazole in crotamiton and glycol salicylate which is prepared by warming at about 70 to 80°C, and the mixture is well stirred and kneaded to give an ointment.

Example 3 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Lanconazole	2.0
Crotamiton	5.0
Polyethylene glycol 400	40.0
Polyethylene glycol 4000	53.0
Totally	100.0 g

Polyethylene glycol 4000 is dissolved by warming on a water bath, and thereto is added a solution of lanconazole in crotamiton and polyethylene glycol 400, which is prepared by warming at about 70 to 80°C, and the mixture is well stirred, and thereafter, cooled and kneaded until it becomes semisolid to give an ointment.

Example 4 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	2.0
Peppermint oil	5.0
Isopropyl myristate	5.0
Glycerin monostearate	3.0
White vaseline	85.0
Totally	100.0 g

White vaseline is dissolved by warming on a water bath, and thereto is added a solution of bifonazole in peppermint oil, isopropyl myristate and glycerin monostearate, which is prepared by warming at about 70 to 80°C, and the mixture is well stirred, and thereafter, cooled and kneaded until it becomes semisolid to give an ointment.

Example 5 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	0.5
Glycol salicylate	5.0
<i>l</i> -Menthol	2.0
Lauromacrogol	2.5
White vaseline	90.0
Totally	100.0 g

White vaseline is dissolved by warming on a water bath, and thereto is added a solution of bifonazole in glycol salicylate, *l*-menthol and lauromacrogol, which is prepared by warming at about 70 to 80°C, and the mixture is well stirred, and thereafter, cooled and kneaded until it becomes semisolid to give an ointment.

Example 6 (Ointment)

An ointment is prepared by the following formulation.

(Components)	(Amount)
Terbinafine hydrochloride	1.0
Crotamiton	10.0
2 % Aqueous sodium hydroxide solution	10.0
Sorbitan sesqui-oleate	6.0
Octyldodecanol	5.0
White vaseline	68.0
Totally	100.0 g

White vaseline is dissolved by warming on a water bath, and thereto is added a solution of terbinafine hydrochloride in crotamiton, 2% aqueous sodium hydroxide solution, sorbitan sesqui-oleate and octyldodecanol, which is prepared by warming at about 70 to 80°C, and the mixture is well stirred, and thereafter, cooled and kneaded until it becomes semisolid to give an ointment.

Example 7 (Cream preparation)

A cream preparation is prepared by the following formulation.

(Components)	(Amount)
Butenafine hydrochloride	0.5
Glycol salicylate	2.0
Peppermint oil	1.0
2 % Aqueous sodium hydroxide solution	3.0
White vaseline	25.0
Stearyl alcohol	15.0
Propylene glycol	10.0
Sodium laurylsulfate	1.5
Lauromacrogol	2.0
Ethyl parahydroxybenzoate	0.025
Butyl parahydroxybenzoate	0.015
Purified water	39.96
Totally	100.0 g

Butenafine hydrochloride is dissolved in glycol salicylate, peppermint oil, a 2 % aqueous sodium hydroxide solution and lauromacrogol by warming at about 70 to 80°C. Thereto are added white vaseline, stearyl alcohol, and butyl parahydroxybenzoate, and the mixture is dissolved and well stirred on a water bath and kept at about 70 to 80°C on a water bath. To the mixture is added a solution of other components which is previously prepared by dissolving them in purified

EP 0 715 856 A1

water and warming at about 70 to 80°C. The mixture is well mixed and stirred until it becomes semisolid to give a cream preparation.

Example 8 (Cream preparation)

A cream preparation is prepared by the following formulation.

(Components)	(Amount)
Lanoconazole	1.0
Crotamiton	10.0
<i>l</i> -Menthol	2.0
2 % Aqueous sodium hydroxide solution	10.0
White vaseline	10.0
Cetanol	5.0
Stearyl alcohol	15.0
Propylene glycol	10.0
Sodium laurylsulfate	1.0
Lauromacrogol	2.0
Ethyl parahydroxybenzoate	0.025
Butyl parahydroxybenzoate	0.015
Purified water	33.96
Totally	100.0 g

Lanoconazole is dissolved in crotamiton, *l*-menthol, a 2 % aqueous sodium hydroxide solution and lauromacrogol by warming at about 70 to 80°C. Thereto are added white vaseline, cetanol, stearyl alcohol and butyl parahydroxybenzoate, and the mixture is dissolved by warming and well stirred on a water bath and kept at about 70 to 80°C on a water bath. To the mixture is added a solution of other components which is previously prepared by dissolving them in purified water and warming at about 70 to 80°C. The mixture is well mixed and stirred until it becomes semisolid to give a cream preparation.

EP 0 715 856 A1

Example 9 (Cream preparation)

A cream preparation is prepared by the following formulation.

(Components)	(Amount)
Amorolfine hydrochloride	1.0
Crotamiton	5.0
Methyl salicylate	2.0
Diisopropyl adipate	10.0
2 % Aqueous sodium hydroxide solution	5.0
Lipophilic glycerin monooleate	5.0
Plastibase	72.0
Totally	100.0 g

Amorolfine hydrochloride is dissolved in crotamiton, methyl salicylate, diisopropyl adipate, a 2 % aqueous sodium hydroxide solution and lipophilic glycerin monooleate by warming at about 70 to 80°C, and thereto is added plastibase. The mixture is well mixed and stirred until it becomes homogenous to give a cream preparation.

Example 10 (Cream preparation)

A cream preparation is prepared by the following formulation.

(Components)	(Amount)
Liranaftate	1.0
Crotamiton	10.0
Peppermint oil	3.0
Diisopropyl adipate	5.0
White vaseline	25.0
Stearyl alcohol	25.0
1,3-Butylene glycol	5.0
Sorbitan sesqui-oleate	2.0
Polyoxyl 40 stearate	5.0
Methyl parahydroxybenzoate	0.025
Propyl parahydroxybenzoate	0.015
Purified water	18.96
Totally	100.0 g

Liranaftate is dissolved in crotamiton, peppermint oil, diisopropyl adipate, sorbitan sesqui-oleate and polyoxyl 40 stearate by warming at about 70 to 80°C, and thereto are added white vaseline, stearyl alcohol, and propyl parahydroxybenzoate. The mixture is well dissolved and stirred by warming on a water bath, and kept at about 70 to 80°C. To the mixture is added a solution of the other components, which is previously prepared by dissolving them in purified water

and warmed at about 70 to 80°C, and the mixture is well mixed and stirred until it becomes semisolid to give a cream preparation.

Example 11 (Gel preparation)

A gel preparation is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	0.5
Crotamiton	1.0
Denatured alcohol	66.5
Hydroxypropylmethyl cellulose	0.5
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	25.0
Diisopropanolamine	1.5
Totally	100.0 g

Bifonazole is dissolved in a mixture of crotamiton, a part of denatured alcohol and 1,3-butylene glycol by stirring well. Separately, to a homogeneous mixture of hydroxypropylmethyl cellulose in a part of denatured alcohol is added a 4 % aqueous carboxyvinyl polymer solution and stirred. Thereto is added diisopropanolamine, and the mixture is made homogeneous by stirring to give a gel base. To the gel base is added the above bifonazole-containing solution, and the mixture is homogeneously stirred to give a gel preparation.

Example 12 (Gel preparation)

A gel preparation is prepared by the following formulation.

(Components)	(Amount)
Neticonazole hydrochloride	1.0
Crotamiton	5.0
Methyl salicylate	2.0
Denatured alcohol	60.4
Hydroxypropylmethyl cellulose	1.0
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	25.0
Diisopropanolamine	0.6
Totally	100.0 g

Neticonazole hydrochloride is dissolved in a mixture of crotamiton, methyl salicylate, a part of denatured alcohol and 1,3-butylene glycol by stirring well. Separately, to a homogeneous mixture of hydroxypropylmethyl cellulose in a part of denatured alcohol is added a 4 % aqueous carboxyvinyl polymer solution and stirred, and thereto is added diisopropanolamine, and the mixture is made homogeneous by stirring to give a gel base. To the gel base is added the

above neticonazole hydrochloride-containing solution, and the mixture is homogeneously stirred to give a gel preparation.

Example 13 (Gel preparation)

A gel preparation is prepared by the following formulation.

(Components)	(Amount)
Terbinafine hydrochloride	3.0
Crotamiton	10.0
Denatured alcohol	50.5
Hydroxypropylmethyl cellulose	1.0
Polyethylene glycol 400	10.0
4 % Aqueous carboxyvinyl polymer solution	25.0
Diisopropanolamine	0.5
Totally	100.0 g

Terbinafine hydrochloride is dissolved in a mixture of crotamiton, a part of denatured alcohol and polyethylene glycol 400 with stirring well. Separately, to a homogeneous mixture of hydroxypropylmethyl cellulose in a part of denatured alcohol is added a 4 % aqueous carboxyvinyl polymer solution and stirred, and thereto is added diisopropanolamine, and the mixture is made homogeneous by stirring to give a gel base. To the gel base is added the above terbinafine hydrochloride-containing solution, and the mixture is homogeneously stirred to give a gel preparation.

Example 14 (Gel preparation)

A gel preparation is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	1.0
<i>l</i> -Menthol	3.0
Denatured alcohol	64.0
Hydroxypropylmethyl cellulose	0.5
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	25.0
Diisopropanolamine	1.5
Totally	100.0 g

Bifonazole is dissolved in a mixture of *l*-menthol, a part of denatured alcohol and 1,3-butylene glycol with stirring well. Separately, to a homogeneous mixture of hydroxypropylmethyl cellulose in a part of denatured alcohol is added a 4 % aqueous carboxyvinyl polymer solution and stirred, and thereto is added diisopropanolamine, and the mixture is made homogeneous by stirring to give a gel base. To the gel base is added the above bifonazole-containing solution, and the mixture is homogeneously stirred to give a gel preparation.

Example 15 (Gel cream preparation)

A gel cream preparation is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	1.0
Crotamiton	3.0
Peppermint oil	1.0
Octyldodecanol	10.0
Glycerin monostearate	0.5
Polyethyleneglycol monostearate (45E.O.)	0.5
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	30.0
2 % Aqueous sodium hydroxide solution	27.5
Purified water	21.5
Totally	100.0 g

Bifonazole is dissolved in a mixture of crotamiton, peppermint oil, octyldodecanol, glycerin monostearate and polyethyleneglycol monostearate (45E.O.) by warming at about 70 to 80°C. Separately, to a 4 % aqueous carboxyvinyl polymer solution are added a 2 % aqueous sodium hydroxide solution, 1,3-butylene glycol and purified water and the mixture is made homogenous by stirring to give a gel substrate, and warmed to about 70 to 80°C. To the gel substrate is added the above active ingredient-containing solution, and emulsified, and mixed homogeneously to give a gel cream preparation.

Example 16 (Gel cream preparation)

A gel cream preparation is prepared by the following formulation.

(Components)	(Amount)
Ketoconazole	2.0
Glycol salicylate	10.0
Crotamiton	5.0
Peppermint oil	3.0
Diisopropyl adipate	15.0
Glycerin monostearate	2.0
Polyoxyl 40 monostearate	2.0
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	25.0
2 % Aqueous sodium hydroxide solution	10.0
Purified water	21.0
Totally	100.0 g

Ketoconazole is dissolved in a mixture of glycol salicylate, crotamiton, peppermint oil, diisopropyl adipate, glycerin monostearate and polyoxyl 40 monostearate by warming at about 70 to 80°C. Separately, to a 4 % aqueous carboxyvinyl polymer solution are added a 2 % aqueous sodium hydroxide solution, 1,3-butylene glycol and purified water and the mixture is made homogenous by stirring to give a gel substrate, and warmed to about 70 to 80°C. To the gel substrate thus obtained is added the above active ingredient-containing solution, and emulsified, and mixed homogeneously to give a gel cream preparation.

Reference Example 1 (Gel cream preparation)

A gel cream preparation is prepared by the same components as those of the above Example 16 except for glycol salicylate, crotamiton and peppermint oil, in the same manner as in Example 16.

(Components)	(Amount)
Ketoconazole	2.0
Diisopropyl adipate	15.0
Glycerin monostearate	2.0
Polyoxyl 40 monostearate	2.0
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	25.0
2 % Aqueous sodium hydroxide solution	10.0
Purified water	39.0
Totally	100.0 g

Example 17 (Gel cream preparation)

A gel cream preparation is prepared by the following formulation.

(Components)	(Amount)
Terbinafine hydrochloride	1.0
Crotamiton	5.0
Isopropyl myristate	10.0
Lauromacrogol	2.0
1,3-Butylene glycol	5.0
4 % Aqueous carboxyvinyl polymer solution	30.0
2 % Aqueous sodium hydroxide solution	35.0
Purified water	12.0
Totally	100.0 g

Terbinafine hydrochloride is dissolved in a mixture of crotamiton, diisopropyl myristate, lauromacrogol and a 2 % aqueous sodium hydroxide solution by warming at about 70 to 80°C. Separately, to a 4 % aqueous carboxyvinyl polymer solution are added the remaining 2 % aqueous sodium hydroxide solution, 1,3-butylene glycol and purified water and the mixture is made homogenous by stirring to give a gel substrate, and warmed to about 70 to 80°C. To the gel substrate thus obtained is added the above active ingredient-containing solution, and emulsified, and mixed homogeneously to give a gel cream preparation.

Example 18 (Gel cream preparation)

A gel cream preparation is prepared by the following formulation.

(Components)	(Amount)
Lanconazole	1.0
<i>l</i> -Menthol	3.0
Diisopropyl adipate	10.0
Octyldodecanol	10.0
Glycerin monostearate	2.5
Polyoxyl 40 monostearate	2.5
1,3-Butylene glycol	10.0
4 % Aqueous carboxyvinyl polymer solution	25.0
2 % Aqueous sodium hydroxide solution	20.0
Purified water	16.0
Totally	100.0 g

Lanconazole is dissolved in a mixture of *l*-menthol, diisopropyl adipate, octyldodecanol, glycerin monostearate and polyoxyl 40 monostearate by warming at about 70 to 80°C. Separately, to a 4 % aqueous carboxyvinyl polymer solution are added a 2 % aqueous sodium hydroxide solution, 1,3-butylene glycol and purified water and the mixture is

EP 0 715 856 A1

made homogenous by stirring to give a gel substrate, and warmed to about 70 to 80°C. To the gel substrate thus obtained is added the above active ingredient-containing solution, and emulsified, and mixed homogeneously to give a gel cream preparation.

Example 19 (Solution preparation)

A solution preparation is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	1.0
Peppermint oil	5.0
Polyethylene glycol 400	q.s.
Totally	100.0 ml

Bifonazole is dissolved in peppermint oil by warming at about 70 to 80°C. To the mixture is added polyethylene glycol 400, and the mixture is made homogenous by stirring. The total volume thereof is adjusted to 100 ml, and the mixture is filtered to give a solution preparation.

Example 20 (Solution preparation)

A solution preparation is prepared by the following formulation.

(Components)	(Amount)
Bifonazole	1.0
Crotamiton	5.0
Polyethylene glycol 400	10.0
Purified water	20.0
Denatured alcohol	q.s.
Totally	100.0 ml

Bifonazole is dissolved in a mixture of crotamiton and polyethylene glycol 400 by warming at about 70 to 80°C. To the mixture is added purified water, and thereto is further added denatured alcohol, and the mixture is made homogenous by stirring. The total volume thereof is adjusted to 100 ml, and the mixture is filtered to give a solution preparation.

Reference Example 2 (Solution preparation)

A solution preparation is prepared by the same components as those of Example 20 except for crotamiton, in the same manner as Example 20.

(Components)	(Amount)
Bifonazole	1.0
Polyethylene glycol 400	10.0
Purified water	20.0
Denatured alcohol	q.s.
Totally	100.0 ml

Example 21 (Solution preparation)

A solution preparation is prepared by the following formulation.

(Components)	(Amount)
Neticonazole hydrochloride	3.0
Crotamiton	5.0
Methyl salicylate	1.0
Methyl ethyl ketone	20.0
Propylene glycol	10.0
Denatured alcohol	q.s.
Totally	100.0 ml

Neticonazole hydrochloride is dissolved in a mixture of crotamiton, methyl salicylate and methyl ethyl ketone. To the mixture are added propylene glycol and denatured alcohol, and the mixture is made homogenous by stirring. The total volume of the mixture is adjusted to 100 ml, and the mixture is filtered to give a solution preparation.

Example 22 (Solution preparation)

A solution preparation is prepared by the following formulation.

(Components)	(Amount)
Terbinafine hydrochloride	1.0
Glycol salicylate	5.0
Denatured alcohol	60.0
1,3-Butylene glycol	20.0
Purified water	q.s.
Totally	100.0 ml

EP 0 715 856 A1

Terbinafine hydrochloride is dissolved in a mixture of glycol salicylate and a part of denatured alcohol, and thereto are added purified alcohol and 1,3-butylene glycol, and further thereto is added the remaining denatured alcohol. The mixture is made homogenous by stirring, and the total volume thereof is adjusted to 100 ml. The mixture is filtered to give a solution preparation.

Example 23 (Solution preparation)

A solution preparation is prepared by the following formulation.

(Components)	(Amount)
Liranaftate	0.5
Methyl salicylate	2.5
Diethyl sebacate	5.0
Purified water	10.0
Denatured alcohol	q.s.
Totally	100.0 ml

Liranaftate is dissolved in a mixture of methyl salicylate, diethyl sebacate and a part of denatured alcohol, and thereto is added purified water, and further added the remaining denatured alcohol. The mixture is made homogeneous by stirring, and the total volume thereof is adjusted to 100 ml, and the mixture is filtered to give a solution preparation.

Experiment 1

Penetration test into the stratum corneum of antifungal agents:

The penetration into the stratum corneum was tested on the gel cream preparation of the above Example 16 (referred to as Gel cream preparation A), the gel cream preparation of Reference Example 1 (referred to as Gel cream preparation B), the solution preparation of Example 20 (referred to as Solution preparation A) and the solution preparation of Reference Example 2 (referred to as Solution preparation B) in the following manner.

Method:

A test preparation was applied to an area of 5 x 5 cm at the inside of human upper arm at a dose of each 10 ml or 10 g, and allowed to stand for 6 hours. The test composition remained at the applied part was wiped off by an absorbent cotton soaked with 70 % aqueous ethanol solution. Subsequently, a cellophane tape was applied to the surface of the skin at the same area, and pushed thereon, and tore off to have the stratum corneum peeled. These procedures by the cellophane tape were repeated ten times with using a new cellophane tape every time, and the stratum corneum was completely peeled off. The cellophane tapes thus obtained are collected, and extracted with ethanol. The amount of bifonazole or ketoconazole (active antifungal agent in a test composition) in the stratum corneum was determined by high performance liquid chromatography.

Results: The results are shown in Table 1.

Table 1

Test preparation	Amount of ketoconazole in the stratum corneum (µg)	Amount of bifonazole in the stratum corneum (µg)
Gel cream preparation A (Ex. 16)	18.13	-
Gel cream preparation B (Ref. Ex. 1)	1.05	-
Solution preparation A (Ex. 20)	-	14.23
Solution preparation B (Ref. Ex. 2)	-	8.48

Claims

1. In a composition containing as an active ingredient an antifungal agent having a high affinity for keratin in a base for an external preparation, wherein the improvement comprises incorporating one or more oily liquid substances selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol to prepare an antifungal composition for external use being retentive in the stratum corneum.
2. The antifungal composition for external use being retentive in the stratum corneum according to claim 1, wherein the antifungal agent having a high affinity for keratin is one or more agents selected from the group consisting of butenafine hydrochloride, bifonazole, neticonazole hydrochloride, ketoconazole, lanoconazole, terbinafine hydrochloride, amorolfine hydrochloride and liranafate.
3. The antifungal composition for external use being retentive in the stratum corneum according to any one of claims 1 and 2, wherein the antifungal agent having a high affinity for keratin is contained in an amount of 0.5 to 3.0 % by weight based on the whole weight of the composition.
4. The antifungal composition for external use being retentive in the stratum corneum according to any one of claims 1 to 3, wherein one or more oily liquid substances selected from the group consisting of methyl salicylate, glycol salicylate, crotamiton, and peppermint oil or menthol are contained in an amount of 1 to 10 % by weight based on the whole weight of the composition.
5. The antifungal composition for external use being retentive in the stratum corneum according to any one of claims 1 to 4, which is in the form of an ointment, a cream preparation, a gel preparation, a gel cream preparation or a solution preparation.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP95/00773

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁶ A61K47/08, 47/14, 47/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁶ A61K47/08, 47/14, 47/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 60-61518, A (Hisamitsu Pharmaceutical Co., Ltd.), April 9, 1985 (09. 04. 85), Lines 5 to 11, lower left column, page 1 (Family: none)	1 - 5
A	JP, 2-292219, A (Hoyu Co., Ltd.), December 3, 1990 (03. 12. 90), Lines 5 to 8, lower left column, page 1 (Family: none)	1 - 5

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
May 29, 1995 (29. 05. 95)Date of mailing of the international search report
June 20, 1995 (20. 06. 95)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.